Intezyne Technologies is a clinical-stage biopharmaceutical company developing novel anti-cancer therapies, including IT-139 (a Cancer Resistance Pathway inhibitor) and IT-141 (a topoisomerase I inhibitor). IT-139 is being developed for pancreatic, gastric and BRAF-mutated cancers, while IT-141 targets colorectal and breast cancers. IT-139 has previously received Orphan Drug Designation for pancreatic cancer; preclinical data and a completed Phase 1 safety study support potential benefit in its target indications. The company cites poor survival rates in pancreatic and advanced gastric cancers to underscore the unmet need its programs address. Intezyne plans to advance IT-139 and IT-141 through Phase 1/2 trials and to prioritize which indications to pursue based on compelling data and development rationale. The company recently closed a financing that strengthens its balance sheet as it progresses development and seeks strategic partnerships.

Total raised

$10M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2017